Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years-Reference-Cited by-同舟云学术

Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years

Published:2019-08 Issue:8 Volume:14 Page:735-740
ISSN:1746-0751
Container-title:Regenerative Medicine
language:en
Short-container-title:Regenerative Medicine

Author:

Knoepfler Paul S¹²^ORCID

Affiliation:

1. Department of Cell Biology & Human Anatomy, University of California Davis, Davis, CA 95616, USA

2. Institute of Pediatric Regenerative Medicine, Shriners Hospital for Children Northern California, Sacramento, CA 95817, USA

Abstract

Aim: The industry of unproven stem cell clinics has rapidly mushroomed throughout the USA, posing risks to patients and the research field. In this study, the aim was to better define how this industry changes. Methods: I analyzed a large cohort of US stem cell clinic firms and their distinct clinic locations as defined in 2015–2016 for their status now in 2019. Results: About a quarter of the firms no longer marketed stem cells. Some lacked active websites, while others dropped stem cell services. Even so, the total number of clinics in this group increased because some firms greatly expanded their clinic numbers. Conclusion: Overall, the unproven clinic industry is a moving target requiring ongoing study and regulatory oversight.

Publisher

Future Medicine Ltd

Subject

Embryology,Biomedical Engineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/rme-2019-0064

Reference28 articles.

1. Bench to bedside: Current advances in regenerative medicine

2. Call for fellowship programs in stem cell-based regenerative and cellular medicine: new stem cell training is essential for physicians

3. Translational strategies and challenges in regenerative medicine

4. Confronting stem cell hype

5. Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies;Regenerative Medicine;2023-10-23

2. Stromal vascular fraction in the treatment of myositis;Cell Death Discovery;2023-09-19

3. Unproven Stem Cell-Based Interventions: Addressing Patients’ Unmet Needs or Causing Patient Harms?;Philosophy and Medicine;2023

4. Development of a student-driven undergraduate program in regenerative medicine;Regenerative Medicine;2022-10

5. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products;Cytotherapy;2022-07